OncoBone Therapeutics

OncoBone Therapeutics is a Paris-based, privately held virtual CRO providing specialized preclinical project management and consulting services focused on osteoimmuno-oncology and bone metastasis models. Founded by seasoned scientists with deep CRO experience, the company operates as a service provider rather than a traditional drug developer, though its research has identified a novel compound, OBP-004. Its business model is built on leveraging an extensive network of high-quality CRO partners to offer clients efficient, expert-led program management in a niche but critical area of oncology research.

Virtual CRO model leveraging deep scientific expertise in osteoimmuno-oncology and a global network of preclinical research partners to manage and accelerate client drug development programs.

OncoBone competes with large global preclinical CROs (e.g., Charles River, Labcorp) that offer broad capabilities and with smaller niche consultants. Its differentiation is its deep, specific focus on bone metastasis models and its virtual, high-touch project management model, which may be more agile and expert-driven than larger competitors.